FDA Approves Lilly’s Foundayo™: First Anytime GLP-1 Weight Loss Pill
The U.S. Food and Drug Administration has approved Foundayo (orforglipron) for adults with obesity or adults with overweight who have weight-related health conditions. The approval was announced from Indianapolis on April 1, 2026.
Clinical trial findings
Foundayo was evaluated in the ATTAIN Phase 3 program. More than 4,500 people enrolled across two global trials.
- ATTAIN-1 randomized 3,127 adults without diabetes across multiple countries. The trial lasted 72 weeks and compared various doses to placebo.
- ATTAIN-2 enrolled over 1,600 adults with type 2 diabetes. It also ran for 72 weeks and tested multiple doses versus placebo.
In ATTAIN-1, participants who stayed on the highest dose lost an average 27.3 pounds, or 12.4 percent of body weight. The corresponding placebo group lost 2.2 pounds, or 0.9 percent.
Across all treated participants, regardless of completion, average weight loss was about 25 pounds, or 11.1 percent. Placebo participants lost 5.3 pounds, or 2.1 percent.
Impact on health markers
Foundayo produced improvements in several cardiovascular risk indicators. These included smaller waist circumference, lower non-HDL cholesterol, reduced triglycerides, and lower systolic blood pressure.
Availability and cost
Foundayo will be offered through LillyDirect with free home delivery. Prescriptions are being accepted immediately, with shipping beginning April 6, 2026.
People with eligible commercial insurance may pay as little as $25 per month with a savings card. Self-pay pricing starts at $149 per month for the lowest dose. Some Medicare Part D beneficiaries may access the drug for about $50 per month starting July 1, 2026.
How Foundayo is taken
Foundayo is a once-daily oral GLP-1 receptor agonist in small-molecule form. It can be taken any time of day without food or water restrictions.
The medicine comes in multiple tablet strengths, including 0.8 mg through 17.2 mg formulations. Patients should swallow tablets whole and follow their prescriber’s instructions.
Safety and precautions
Use of Foundayo with other GLP-1 receptor agonists is not recommended. Safety in children is unknown.
The drug carries a warning about thyroid tumors, including thyroid cancer. People should report neck lumps, hoarseness, trouble swallowing, or breathing problems to their healthcare provider.
- Do not use Foundayo if you or a family member had medullary thyroid carcinoma (MTC).
- Do not use Foundayo if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Common side effects include nausea, constipation, diarrhea, vomiting, indigestion, abdominal pain, and headache. Other effects reported were swollen belly, fatigue, belching, heartburn, gas, and hair loss.
There is a pregnancy exposure registry for women who take Foundayo during pregnancy. Oral birth control pills may be less effective during use. Providers may recommend alternative contraception for 30 days after starting and after each dose increase.
Origins and global plans
Orforglipron was discovered by Chugai Pharmaceutical Co., Ltd. and licensed to Lilly in 2018. Lilly has submitted the medicine for review in more than 40 countries.
The company plans to launch Foundayo in approved markets shortly after regulatory clearance.
Voices from the field
Experts highlighted the convenience of a once-daily pill. They noted that flexibility may help people start and stay on treatment.
Lilly leaders said the oral option could broaden access and reduce barriers. Patient advocates welcomed the additional treatment choice for obesity care.
FDA approval marks a new oral option in obesity treatment. The FDA approved Foundayo, an anytime GLP-1 weight loss pill developed by Lilly. For more details, visit Filmogaz.com or contact 1-800-545-5979.
